12 citations
,
February 2014 in “PLoS ONE” This study observed high expression of mTOR pathway effectors in fibrous papules and TSC-associated angiofibromas, suggesting that topical rapamycin might be an effective treatment for fibrous papules.
In this study, researchers found that the health state utility of moderate facial angiofibroma in Tuberous Sclerosis Complex patients is significantly lower compared to almost-clear facial angiofibroma, indicating that treatment for the condition can substantially improve quality of life.
36 citations
,
January 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” This article reviews the connection between PI3K-AKT-mTOR pathway mutations and heritable skin diseases characterized by tissue overgrowth, but it reports no new clinical results.
March 2026 in “Voprosy dermatologii i venerologii/Dermatologiâ ža̋ne veneralogiâ ma̋selelerì” This literature review highlights the critical importance of early dermatological diagnosis of tuberous sclerosis, focusing on its genetic basis, dermatological markers, and the role of genetic testing and multidisciplinary support, while discussing treatment options like mTOR inhibitors and their limitations.
April 2003 in “Journal of Cutaneous Medicine and Surgery” Lasers are effective for some skin conditions but can cause side effects like scarring and pigment changes; careful selection is important, and botulinum toxin type A is successful in reducing sweat in palmar hyperhidrosis.